Physician profile
Paul Mcfarlane
NPI 1356969653
$1,877.42
in general payments reported to CMS, 2019-2025
13 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $80.80 · 2023: $430 · 2024: $544 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $619.52 | 2024-2025 | Yeztugo, Biktarvy, Epclusa |
| Viiv Healthcare Company | $511.06 | 2024-2025 | Cabenuva, Apretude |
| Abbvie INC. | $181.24 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $125.00 | 2023 | Terlivaz |
| Pfizer INC. | $110.94 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $110.66 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $103.60 | 2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $28.70 | 2022 | |
| Lilly USA, LLC | $24.53 | 2023 | Taltz |
| Novo Nordisk INC | $18.92 | 2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $16.49 | 2022 | |
| Neurelis, INC. | $13.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.